Impact of availability of anti-vascular endothelial growth factor therapy on visual impairment and blindness due to neovascular age-related macular degeneration.
John P
JP
Campbell
Susan B
SB
Bressler
Neil M
NM
Bressler
D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001766:Blindness / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D005260:Female; D006801:Humans; D017075:Laser Coagulation; D008297:Male; D010778:Photochemotherapy; D015995:Prevalence; D012189:Retrospective Studies; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*; D015354:Vision, Low / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D014792:Visual Acuity / Q000502:physiology; D019987:Persons with Visual Disabilities / Q000706:statistics & numerical data*; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy*
D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A